Jennifer M Weiss1, David Skaggs, John Tanner, Vernon Tolo. 1. Children's Orthopaedic Center, Children's Hospital-Los Angeles, 4650 Sunset Boulevard, Mailstop #69, Los Angeles, CA, 90027, USA, jweiss@chla.usc.edu.
Abstract
STUDY DESIGN: Review of the use of Cell Saver in a non-randomized group of patients undergoing spinal fusion for scoliosis. OBJECTIVES: To determine the efficacy of the use of Cell Saver for spinal fusions for scoliosis. Although Cell Saver is widely used in scoliosis surgery, it is not clear whether its use decreases the need for other transfusions or whether there are certain patients more likely to benefit from its use. The blood collected by Cell Saver intraoperatively is not always of sufficient volume to be returned to the patient, and there are no current guidelines addressing the amount that is likely to be returned to the patient. PURPOSE: The purpose of this study was to determine: Does use of Cell Saver reduce the need for other transfusions in scoliosis surgery? Is there an amount of blood loss at which Cell Saver is likely to be returned? MATERIALS AND METHODS: The study group consisted of 95 children who had undergone posterior spinal fusion between January 2002 and March 2004 with one of two surgeons. One surgeon used Cell Saver, the other surgeon did not. Of the total, 58 patients who underwent posterior spinal fusion with the use of Cell Saver (group 1) were compared with the 37 (group 2) who underwent the same procedure without the use of Cell Saver. RESULTS: Of those in group 1, 34 received Cell Saver blood back as an intraoperative autologous transfusion (IAT) (59%). Patients in the Cell Saver group were just as likely to receive non-Cell Saver transfusions as those in the control group (P = 0.12). Of the 39 patients who lost more than 500 cc of blood, 34 received IAT (87%). No patient who lost less than 500 cc of blood received IAT. CONCLUSION: The use of Cell Saver does not reduce the need for other transfusions in scoliosis surgery. The amount of blood loss at which Cell Saver is likely to be returned is 500 cc. We demonstrated no benefit in the use of Cell Saver in our patient population.
STUDY DESIGN: Review of the use of Cell Saver in a non-randomized group of patients undergoing spinal fusion for scoliosis. OBJECTIVES: To determine the efficacy of the use of Cell Saver for spinal fusions for scoliosis. Although Cell Saver is widely used in scoliosis surgery, it is not clear whether its use decreases the need for other transfusions or whether there are certain patients more likely to benefit from its use. The blood collected by Cell Saver intraoperatively is not always of sufficient volume to be returned to the patient, and there are no current guidelines addressing the amount that is likely to be returned to the patient. PURPOSE: The purpose of this study was to determine: Does use of Cell Saver reduce the need for other transfusions in scoliosis surgery? Is there an amount of blood loss at which Cell Saver is likely to be returned? MATERIALS AND METHODS: The study group consisted of 95 children who had undergone posterior spinal fusion between January 2002 and March 2004 with one of two surgeons. One surgeon used Cell Saver, the other surgeon did not. Of the total, 58 patients who underwent posterior spinal fusion with the use of Cell Saver (group 1) were compared with the 37 (group 2) who underwent the same procedure without the use of Cell Saver. RESULTS: Of those in group 1, 34 received Cell Saver blood back as an intraoperative autologous transfusion (IAT) (59%). Patients in the Cell Saver group were just as likely to receive non-Cell Saver transfusions as those in the control group (P = 0.12). Of the 39 patients who lost more than 500 cc of blood, 34 received IAT (87%). No patient who lost less than 500 cc of blood received IAT. CONCLUSION: The use of Cell Saver does not reduce the need for other transfusions in scoliosis surgery. The amount of blood loss at which Cell Saver is likely to be returned is 500 cc. We demonstrated no benefit in the use of Cell Saver in our patient population.
Authors: M N Mayer; M de Montalembert; F Audat; M C Brusset; B Houfani; J Merckx; G Barrier; C Gazengel Journal: Vox Sang Date: 1996 Impact factor: 2.144
Authors: Lisa Eisler; Stanford Chihuri; Lawrence G Lenke; Lena S Sun; David Faraoni; Guohua Li Journal: Transfusion Date: 2021-11-10 Impact factor: 3.157
Authors: José A A Oliveira; Fernando A M Façanha Filho; Francisco V Fernandes; Paulo C Almeida; Vládia F de Oliveira; Saulo R Lima Verde Journal: J Spine Surg Date: 2017-03